MSB 6.07% $1.01 mesoblast limited

Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA, page-19

  1. 1,904 Posts.
    lightbulb Created with Sketch. 491
    Can't be definitive without going through the actual review process.

    If it's denied at review for one reason or the other it can't be put back to being ill-advised.
    Last edited by pld89: 26/03/24
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.